BACKGROUND: Accumulating evidence suggests that cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) is involved in oesophageal adenocarcinogenesis. PGE2 exerts its biological action by binding to specific receptors (EP1, EP2, EP3 and EP4). AIM: To investigate which PGE2 receptor subtypes regulate PGE2 signals in the oesophageal adenocarcinoma sequence. METHODS: Expression was determined in oesophageal biopsies from 85 patients with oesophagitis, Barrett's metaplasia, intraepithelial neoplasia, oesophageal adenocarcinoma and normal oesophagus. Levels of mRNA and protein expression were determined by quantitative PCR, immunohistochemistry and western-blot. Expression of EP receptors was also determined in response to acid and bile exposure in the Barrett's adenocarcinoma cell line OE33. RESULTS: All four EP receptors subtypes were expressed in human oesophageal tissues. COX-2 and, especially, EP2 were increased in the Barrett's metaplasia-intraepithelial neoplasia-adenocarcinoma sequence. Expression of the EP4 receptor protein was increased in oesophageal adenocarcinoma. In contrast, expression levels of COX-1 and EP3 receptor were decreased along the sequence. No differences in EP1 expression were found. Treatment with the bile acid deoxycholate increased COX-2, EP1, EP2 and EP4 expression in OE33 cells. CONCLUSIONS: Our data suggest that in addition to COX-2, EP2 and EP4 receptors could be a selective target in the prevention and/or treatment of the Barrett's-associated adenocarcinoma.
BACKGROUND: Accumulating evidence suggests that cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) is involved in oesophageal adenocarcinogenesis. PGE2 exerts its biological action by binding to specific receptors (EP1, EP2, EP3 and EP4). AIM: To investigate which PGE2 receptor subtypes regulate PGE2 signals in the oesophageal adenocarcinoma sequence. METHODS: Expression was determined in oesophageal biopsies from 85 patients with oesophagitis, Barrett's metaplasia, intraepithelial neoplasia, oesophageal adenocarcinoma and normal oesophagus. Levels of mRNA and protein expression were determined by quantitative PCR, immunohistochemistry and western-blot. Expression of EP receptors was also determined in response to acid and bile exposure in the Barrett's adenocarcinoma cell line OE33. RESULTS: All four EP receptors subtypes were expressed in human oesophageal tissues. COX-2 and, especially, EP2 were increased in the Barrett's metaplasia-intraepithelial neoplasia-adenocarcinoma sequence. Expression of the EP4 receptor protein was increased in oesophageal adenocarcinoma. In contrast, expression levels of COX-1 and EP3 receptor were decreased along the sequence. No differences in EP1 expression were found. Treatment with the bile aciddeoxycholate increased COX-2, EP1, EP2 and EP4 expression in OE33 cells. CONCLUSIONS: Our data suggest that in addition to COX-2, EP2 and EP4 receptors could be a selective target in the prevention and/or treatment of the Barrett's-associated adenocarcinoma.
Authors: Andrew K Joe; Felice Schnoll-Sussman; Robert S Bresalier; Julian A Abrams; Hanina Hibshoosh; Ken Cheung; Richard A Friedman; Chung S Yang; Ginger L Milne; Diane D Liu; J Jack Lee; Kazeem Abdul; Michelle Bigg; Jessica Foreman; Tao Su; Xiaomei Wang; Aqeel Ahmed; Alfred I Neugut; Esther Akpa; Scott M Lippman; Marjorie Perloff; Powel H Brown; Charles J Lightdale Journal: Cancer Prev Res (Phila) Date: 2015-10-15
Authors: David E Fleischer; Robert Odze; Bergein F Overholt; John Carroll; Kenneth J Chang; Ananya Das; John Goldblum; Daniel Miller; Charles J Lightdale; Jeffrey Peters; Richard Rothstein; Virender K Sharma; Daniel Smith; Victor Velanovich; Herbert Wolfsen; George Triadafilopoulos Journal: Dig Dis Sci Date: 2010-04-20 Impact factor: 3.199
Authors: Jeffrey Molendijk; Cathryn M Kolka; Henry Cairns; Sandra Brosda; Ahmed Mohamed; Alok K Shah; Ian Brown; Mark P Hodson; Thomas Hennessy; Guanghao Liu; Thomas Stoll; Renee S Richards; Michael Gartside; Kalpana Patel; Nicholas J Clemons; Wayne A Phillips; Andrew Barbour; Johan A Westerhuis; Michelle M Hill Journal: Clin Transl Med Date: 2022-05
Authors: James L Araujo; Nasser K Altorki; Joshua R Sonett; Adriana Rodriguez; Kivilcim Sungur-Stasik; Cathy F Spinelli; Alfred I Neugut; Julian A Abrams Journal: Therap Adv Gastroenterol Date: 2016-07-15 Impact factor: 4.409